Caplacizumab (ALX-0081)November 27, 2018
Caplacizumab is a subcutaneously injected biologic agent proposed as an adjunct to standard care for acquired thrombotic thrombocytopenic purpura. It is a bivalent single-domain anti-von Willebrand factor (VWF) nanobody that inhibits the binding of VWF to platelets to prevent the early stages of blood clot formation. Nanobodies are much smaller than conventional monoclonal antibodies, allowing for more rapid distribution, onset of action, and clearance.
If you have a Hayes login, click here to view the full report on the Knowledge Center.